CRISPR Therapeutics has reported positive results for a phase 1 study evaluating CTX110, its chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory nonHodgkin’s lymphoma in patients who have received at least two prior lines of therapy.

In the open-label, multicenter trial, 12 participants received CTX110, with primary endpoints defined as incidence of dose-limiting toxicities and overall response rate. Secondary endpoints include duration of response, progression-free survival and overall survival.

Preliminary results show complete remission of advanced B-cell lymphoma in some participants, but the company disclosed that one patient who received the treatment died.

CRISPR has partnered with Vertex Pharmaceuticals to conduct additional trials for patients with rare genetic blood disorders.